Skip to main content
Premium Trial:

Request an Annual Quote

DNAPrint Buys 18 Percent of Biofrontera for $1.8M, Expands Drug Pipeline

NEW YORK, July 14 (GenomeWeb News) - DNAPrint Genomics said yesterday that it had purchased an 18-percent share of Leverkusen, Germany-based Biofrontera for 1.5 million ($1.8 million), a prelude to the development of a new pharmaceutical pipeline for DNAPrint. 


DNAPrint said it will add two of Biofrontera's Phase II drugs to its stable for chronic uriticaria and actinic keratosis, called BF-Derm1 and 5-aminolevulonic acid, respectively, the company said. DNAPrint will also add "a series" of drugs that are in pre-clinical development, including a prophylactic migraine treatment, it said.


"The key goal of our pharmaceutical research is the development of test/drug combinations for helping to ensure efficacy with compatible patients," said Hector Gomez, DNAPrint's chief medical officer.


"Over the next several months we plan to expand our relationship with Biofrontera, especially in the drug development arena, and we plan to take advantage of each others' locations to help promote our respective products and services in each others' markets," said Richard Gabriel, president and CEO of DNAPrint.


Gabriel and Gomez will sit on the Biofrontera board of directors in connection with the transaction, the company said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more